News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,502 Results
Type
Article (40892)
Company Profile (267)
Press Release (680333)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204660)
Career Advice (2022)
Deals (35532)
Drug Delivery (110)
Drug Development (81379)
Employer Resources (173)
FDA (16407)
Job Trends (14943)
News (346368)
Policy (32723)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (141)
Alliances (49575)
ALS (169)
Alzheimer's disease (1664)
Antibody-drug conjugate (ADC) (308)
Approvals (16673)
Artificial intelligence (510)
Autoimmune disease (151)
Automation (38)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (188)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (634)
Cancer (4780)
Cardiovascular disease (398)
Career advice (1707)
Career pathing (35)
CAR-T (280)
CDC (44)
Celiac Disease (2)
Cell therapy (739)
Cervical cancer (36)
Clinical research (69540)
Collaboration (1690)
Company closure (4)
Compensation (1155)
Complete response letters (54)
COVID-19 (2709)
CRISPR (87)
C-suite (834)
Cystic fibrosis (143)
Data (6196)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (499)
Diagnostics (6683)
Digital health (48)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (250)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (230)
Earnings (90110)
Editorial (56)
Employer branding (21)
Employer resources (152)
Events (117241)
Executive appointments (970)
FDA (19509)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1462)
Gene editing (192)
Generative AI (43)
Gene therapy (591)
GLP-1 (965)
Government (4655)
Grass and pollen (6)
Guidances (383)
Healthcare (18870)
HIV (58)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (248)
Immuno-oncology (56)
Indications (109)
Infectious disease (2973)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (115)
Intellectual property (246)
Interviews (315)
IPO (16641)
IRA (49)
Job creations (3642)
Job search strategy (1427)
JPM (57)
Kidney cancer (15)
Labor market (84)
Layoffs (546)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (644)
Lymphoma (374)
Machine learning (42)
Management (59)
Manufacturing (790)
MASH (162)
Medical device (13765)
Medtech (13818)
Mergers & acquisitions (19959)
Metabolic disorders (1262)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (313)
Neuropsychiatric disorders (87)
Neuroscience (2885)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4512)
Now hiring (67)
Obesity (592)
Opinion (257)
Ovarian cancer (166)
Pain (197)
Pancreatic cancer (225)
Parkinson's disease (279)
Partnered (33)
Patents (491)
Patient recruitment (482)
Peanut (56)
People (58849)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21679)
Phase 2 (30608)
Phase 3 (22798)
Pipeline (5219)
Policy (279)
Postmarket research (2564)
Preclinical (9195)
Press Release (64)
Prostate cancer (236)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (828)
Real estate (5954)
Recruiting (70)
Regulatory (24460)
Reports (52)
Research institute (2386)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (996)
Venture capital (87)
Weight loss (379)
Women's health (89)
Worklife (18)
Date
Today (150)
Last 7 days (638)
Last 30 days (2057)
Last 365 days (29896)
2026 (3232)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (308)
Arkansas (13)
Asia (39207)
Australia (6407)
California (11241)
Canada (3269)
China (1094)
Colorado (476)
Connecticut (472)
Delaware (335)
Europe (84485)
Florida (1676)
Georgia (354)
Hawaii (3)
Idaho (61)
Illinois (854)
India (64)
Indiana (518)
Iowa (22)
Japan (424)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1375)
Massachusetts (8056)
Michigan (323)
Minnesota (624)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2989)
New Mexico (28)
New York (2963)
North Carolina (1447)
North Dakota (8)
Northern California (5488)
Ohio (331)
Oklahoma (21)
Oregon (41)
Pennsylvania (2269)
Puerto Rico (24)
Rhode Island (47)
South America (1108)
South Carolina (65)
South Dakota (1)
Southern California (4374)
Tennessee (174)
Texas (1735)
United States (39839)
Utah (334)
Vermont (1)
Virginia (259)
Washington D.C. (81)
Washington State (917)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
721,502 Results for "biotheryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Biotheryx Announces U.S. FDA Clearance of Investigational New Drug Application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6
Biotheryx, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for BTX-9341, a novel cyclin-dependent kinase 4/6 (CDK4/6) bifunctional degrader.
May 7, 2024
·
2 min read
Business
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
Biotheryx, Inc. announced it has entered into a Research Collaboration and License agreement with Incyte to discover and develop targeted protein degraders for novel oncology targets.
April 5, 2023
·
3 min read
Drug Development
Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meeting
Biotheryx, Inc. announced two poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2–6, 2023, in Chicago, Illinois and online.
May 25, 2023
·
5 min read
Business
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biotheryx, Inc. today announced the appointment of Tracy Lawhon, J.D., as Chief Development Officer (CDO).
August 24, 2022
·
3 min read
Biotech Beach
Biotheryx to Participate in Wells Fargo 2023 Targeted Protein Degradation Virtual Summit
Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) in areas of high unmet medical need, today announced that members of its senior management team will participate in two panel discussions at the Wells Fargo 2023 Targeted Protein Degradation Virtual Summit.
February 15, 2023
·
1 min read
Biotech Beach
Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting
Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced data presentations on two first-in-class programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting held in Orlando, Florida, on April 14–19, 2023.
April 17, 2023
·
5 min read
Business
Biotheryx Announces Appointment of Jeff Caravella as Chief Financial Officer
Biotheryx, Inc. today announced the appointment of Jeff Caravella as Chief Financial Officer.
April 25, 2022
·
2 min read
Business
BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors
BioTheryX, Inc. today announced that Nancy Miller-Rich has assumed the role of Chair of the BioTheryX Board of Directors.
February 23, 2022
·
2 min read
Biotech Beach
Biotheryx to Present Preclinical Findings on Protein Degrader Programs at 5th Annual Targeted Protein Degradation Summit
Biotheryx, Inc. today announced that it will present preclinical data from its targeted protein degrader programs at the 5th Annual Targeted Protein Degradation Summit, being held October 25-28, 2022, in Boston, Massachusetts.
October 24, 2022
·
2 min read
Business
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX, Inc. today announced the appointment of Philippe Drouet as President and Chief Executive Officer of BioTheryX.
October 28, 2021
·
3 min read
1 of 72,151
Next